

Technology Development Board (TDB) has entered into an agreement on 7th September 2018, with M/s Epygen Biotech Pvt. Ltd, Navi Mumbai for "Epygen Phase I Funding".

About the Project and Product

Epygen Biotech Pvt Ltd is a Biopharmaceutical company, engaged in research and manufacturing of Therapeutic Proteins for Oncology, Cardiovascular and Immune disorders. It is going to launch its entry Biosimilar Recombinant Streptokinase (rSK) in 2019, under Technology license from CSIR-IMTECH. This well-proven technology has been improvised for enhanced product performance and patient safety profile. The company has tied up with CSIR-IMTECH, for scaling up its Biosimilar rSK technology for large-scale production of this critical therapeutic protein at an affordable cost.

They have successfully optimized the technology for pilot scale production of rSK. They have isolated the Streptokinase (SK) gene from Streptococcus equisimilis and cloned it into a T7 polymerase promoter-based expression vector. This expression vector was then transfer into E. coli cells and express the rSK protein as a non-glycosylated polypeptide chain containing around 400 amino acids having a molecular weight of 47 kDa. The Plasmid of this rSK has been transformed to get rid of the traditional Beta Lactum markers and fermented at high cell densities with unique optimization techniques, for over expression. The rSK has been purified by proprietary Downstream Processing and chromatographic techniques. Streptokinase is a protein derived from β -hemolytic Streptococci, which can act as thrombolytic agents and are being used to lyse the already formed blood clots in the body where ischemia may cause fatality. EBPL aims to take this life saving cardiovascular (Thrombolytic) drug to patients in Indian subcontinent and the underprivileged of the world, at an affordable cost but abiding highest quality standards.



Dr. Bindu Dey, Secretary, TDB exchanging the Loan Agreement with Sh. Debayan Sukhamoy Ghosh, Director of M/s Epygen Biotech Pvt. Ltd, Navi Mumbai.

TDB financially supports M/s Epygen Biotech Pvt. Ltd, Navi Mumbai for 'Epygen Phase I Funding'.